UNSPSC 51386202: Olsalazine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H10N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ULS5I8J03O, chemically known as 1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine but generally known as olsalazine, which bears US NIH Compound Identifier 4205. European Medicines Agency schedules Olsalazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09436MIG.

UNSPSC 51386202 Olsalazine, a Commodity code, does not align with the pharmaceutical procurement activity appearing in recent state and local solicitations under this code. The single recent opportunity in the dataset—Seminole County, Florida's IFB for naloxone and drug deactivation systems—lies outside the scope of olsalazine, an oral aminosalicylate used to treat inflammatory bowel disease. The code shows little relevant recent activity tied to its nominal pharmaceutical classification.

The mismatch between the code's intended product and the naloxone procurement suggests either a tagging error in the sourcing system or that olsalazine itself does not drive meaningful state and local purchasing volume at present. Seminole County's June 2026 IFB (IFB60459723LAS, response deadline July 26, 2023) represents the only recent opportunity, and it addresses opioid-reversal and drug-disposal products rather than olsalazine. No other state or local issuing bodies, geographic concentrations, or representative olsalazine-specific opportunities emerge from the available data. This code warrants monitoring for pharmaceutical procurement activity but shows no actionable pursuit signals for vendors in the olsalazine or related aminosalicylate space today.